• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN

DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN

机译：对儿童严重急性呼吸综合征病毒SARS-COV-2诱导特异性免疫的药物应用

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

FIELD: biotechnology; immunology; virology. ;SUBSTANCE: drug application for the prevention of diseases caused by the virus of severe acute respiratory syndrome SARS-CoV-2 in children older than 1 month is described. 6 variants of the application of the tool are presented, including component 1 in the form of an expression vector based on the genome of the recombinant human adenovirus strain of the 26th serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and/or component 2 in the form of an expression vector based on the recombinant genome human adenovirus strain of the 5th serotype, in which E1 and E3 regions with a built-in expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO are deleted: 3, and/or component 3 in the form of an expression vector based on the genome of the recombinant simian adenovirus strain of the 25th serotype, in which E1 and E3 regions with an integrated expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3 are deleted. The claimed components are used both separately and jointly. ;EFFECT: group of inventions provides the creation of a safe and effective remedy that ensures the development of humoral and cellular immune response reactions against the SARS-CoV-2 virus in children older than 1 month, the drug also provides the induction of a humoral immune response comparable to the immune response of an adult and provides an enhanced mucosal response in the respiratory tract.;15 cl, 6 dwg, 8 tbl, 16 ex
机译：领域：生物技术;免疫学;病毒学。 ;物质：对预防由1个月的儿童的严重急性呼吸道综合征SARS-COV-2引起的疾病的药物应用。提出了施用工具的施加的变体，包括基于第26次血清型的重组人腺病毒菌株的基因组的表达载体形式的组分1，其中缺失E1和E3区，以及ORF6- AD26区域由ORF6-AD5代替，其具有从SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3和/或组分2中选择的基于重组基因组人的表达载体的形式的综合表达盒第5次血清型的腺病毒株，其中来自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO选择的内置表达盒的E1和E3区被删除：3和/或形式的组分3基于第25次血清型重组血管腺病毒株的基因组的表达载体，其中，选择从SEQ ID NO：4，SEQ ID NO：2，SEQ ID NO：3中选择的综合表达盒的E1和E3区删除了。要求保护的组件单独和共同使用。 ;效果：发明集团提供了一种安全有效的补救措施，可确保对1个月的儿童的SARS-COV-2病毒进行体液和细胞免疫反应反应的发展，该药物还提供了诱导体液的诱导免疫应答与成年人的免疫应答相当，并在呼吸道中提供增强的粘膜反应。; 15 Cl，6 dwg，8 tbl，16 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号